Cite
Jonas MM, Rhee S, Kelly DA, et al. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study. Hepatology. 2021;74(1):19-27doi: 10.1002/hep.31841.
Jonas, M. M., Rhee, S., Kelly, D. A., Del Valle-Segarra, A., Feiterna-Sperling, C., Gilmour, S., Gonzalez-Peralta, R. P., Hierro, L., Leung, D. H., Ling, S. C., Lobzin, Y., Lobritto, S., Mizuochi, T., Narkewicz, M. R., Sabharwal, V., Wen, J., Kei Lon, H., Marcinak, J., Topp, A., Tripathi, R., & Sokal, E. (2021). Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study. Hepatology (Baltimore, Md.), 74(1), 19-27. https://doi.org/10.1002/hep.31841
Jonas, Maureen M, et al. "Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study." Hepatology (Baltimore, Md.) vol. 74,1 (2021): 19-27. doi: https://doi.org/10.1002/hep.31841
Jonas MM, Rhee S, Kelly DA, Del Valle-Segarra A, Feiterna-Sperling C, Gilmour S, Gonzalez-Peralta RP, Hierro L, Leung DH, Ling SC, Lobzin Y, Lobritto S, Mizuochi T, Narkewicz MR, Sabharwal V, Wen J, Kei Lon H, Marcinak J, Topp A, Tripathi R, Sokal E. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study. Hepatology. 2021 Jul;74(1):19-27. doi: 10.1002/hep.31841. PMID: 33811356; PMCID: PMC8548879.
Copy
Download .nbib